WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 17 fonti

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK

Raccontata da

thehindubusinessline.com

independent.co.uk

hindustantimes.com

ilsole24ore.com

newsbytesapp.com+5 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo2 g fa

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK

Timeline cronologica

martedì 9 giugno 2026·cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
martedì 9 giugno 2026·thehindubusinessline.com
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.

cryptobriefing.com

2 g fa

GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business

GSK is acquiring Nuvalent for $10.6 billion in cash, gaining three late-stage lung cancer therapies including two drugs already under FDA review.

Leggi questa versione → originale

cityam.com3 g fa

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

Leggi questa versione → originale

newsbytesapp.com3 g fa

GSK buys US biopharma company Nuvalent for $10.6B

Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.

Leggi questa versione → originale

statnews.com3 g fa

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

Leggi questa versione → originale

barrons.com3 g fa

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.

Leggi questa versione → originale

martedì 9 giugno 2026·

cityam.com

GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal

GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.

martedì 9 giugno 2026·

endpoints.news

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.

martedì 9 giugno 2026·

statnews.com

GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

martedì 9 giugno 2026·

independent.co.uk

GSK to buy US lung cancer drug specialist Nuvalent for £8bn

The acquisition is thought to be GSK’s biggest deal in more than a decade.

martedì 9 giugno 2026·

lecho.be

GSK rachète Nuvalent pour plus de 10 milliards de dollars

GSK va racheter l'américain Nuvalent pour 10,6 milliards de dollars. L’opération, qui devrait être officialisée au troisième trimestre, offre une prime de 40% par rapport aux près…

martedì 9 giugno 2026·

hindustantimes.com

UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News

martedì 9 giugno 2026·

ilsole24ore.com

Gsk sotto pressione a Londra, pesa l'accordo per l'acquisto di Nuvalent

Operazione da 10,6 mld di dollari con il lancio di un'Opa

martedì 9 giugno 2026·

benzinga.com

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.

martedì 9 giugno 2026·

barrons.com

Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal

Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.

martedì 9 giugno 2026·

benzinga.com

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.

martedì 9 giugno 2026·

newsbytesapp.com

GSK buys US biopharma company Nuvalent for $10.6B

Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.

martedì 9 giugno 2026·

milanofinanza.it

Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk…

L’intesa prevede il lancio di un’offerta pubblica di acquisto su tutte le azioni in circolazione della società americana al prezzo di 124 dollari per azione in contanti

martedì 9 giugno 2026·

ilsole24ore.com

Gsk acquisisce Nuvalent per 10,6 miliardi nel top deal degli ultimi dieci anni

L’accordo attribuisce a Nuvalent una valutazione di circa 124 dollari per azione, con un premio del 40% rispetto all’ultimo prezzo di chiusura

martedì 9 giugno 2026·

economictimes.indiatimes.com

$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent

British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in cancer treatments. The acquisition…

mercoledì 10 giugno 2026·

thisdaylive.com

GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion

GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion

mercoledì 10 giugno 2026·

cryptobriefing.com

GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business

GSK is acquiring Nuvalent for $10.6 billion in cash, gaining three late-stage lung cancer therapies including two drugs already under FDA review.

mercoledì 10 giugno 2026·

morningstar.com

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK

Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK